RARE•benzinga•
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
Summary
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga